登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603368 证券简称：柳药集团 公告编号：2025-053 转债代码：113563 转债简称：柳药转债 广西柳药集团股份有限公司关于以集中竞价交易方式回购股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 广西柳药集团股份有限公司（以下简称"公司"）基于对未来发展前景的信心和对公司长期价值的高度认 可，为推动公司股票价值的合理回归，稳定投资者预期，增强市场信心，维护公司和全体股东的利益， 并进一步落实"提质增效重回报"行动方案，公司拟以集中竞价交易方式回购公司发行的部分人民币普通 股A股股份。主要内容如下： ● 回购股份金额：不低于人民币10,000万元（含），不超过人民币20,000万元（含）。 ● 回购股份资金来源：公司自有资金和自筹资金。 ● 回购股份用途：拟在未来适宜时机用于实施股权激励及/或员工持股计划；若公司未能在本次股份回 购完成后3年内实施上述用途，则未使用的已回购股份将履行相关程序予以注销。 ● 回购股份价格：不超过 ...

Group 1: Company Announcements - Guangshen Railway signed a cooperation agreement for the Guangzhou East Station renovation project with a total investment of approximately 16.66 billion yuan, including a reconstruction compensation investment of about 2.228 billion yuan [1] - Fushun Special Steel announced that Ningbo Meishan Bonded Port Area Jincheng Shazhou intends to make a partial tender offer to acquire 5% of the company's shares at a price of 5.6 yuan per share [2] - China Duty Free Group reported a net profit of 2.6 billion yuan for the first half of 2025, a year-on-year decrease of 20.81%, with total operating revenue of 28.151 billion yuan, down 9.96% [3] - Gaozheng Mining announced that its controlling shareholder, Cangjian Group, reduced its shareholding by 2.76 million shares, bringing its stake down to 57.6% [4] - Sanfeng Intelligent reported that its director Chen Wei is under investigation, but the company's operations remain normal [5] - Guangsheng Group's innovative hepatitis B treatment drug GST-HG141 has successfully enrolled its first participant in a Phase III clinical trial [6] - Western Gold announced plans to acquire 100% of Xinjiang Meisheng for 1.655 billion yuan, with a premium of 1421.66% over the book value [7] - Huqin Technology announced that shareholders holding more than 5% plan to reduce their holdings by up to 4% of the company's shares [8] - Dongshan Precision's subsidiary plans to invest up to 1 billion USD in a high-end printed circuit board project [10] - Yitian Intelligent plans to jointly invest in a private equity fund focusing on artificial intelligence and computing power, with a total subscription amount of 2 billion yuan [11] - *ST Wanfang is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [12] - Ruibeka and its controlling shareholder are also under investigation by the CSRC for similar reasons [13] - BioShares' subsidiary received clinical trial approval for a cat infectious peritonitis mRNA vaccine [14] - Ruipu Bio received the first clinical trial approval for an mRNA vaccine for economic animals in China [15] - Shengke Communication announced that a major fund plans to reduce its holdings by up to 3% of the company's shares [16] - ShenKai Co. announced a capital increase of 15 million yuan in Shandong Future Robotics, a deep-sea operation robot company [18] - Shouchuang Securities plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength [19] Group 2: Financial Performance - Western Mining reported a net profit of 1.869 billion yuan for the first half of the year, a year-on-year increase of 15% [20] - Digital Certification expects a loss of 80 million to 96 million yuan for the first half of the year [21] Group 3: Major Contracts and Share Buybacks - China Communications Construction Company signed new contracts worth 991.054 billion yuan in the first half of the year, a year-on-year increase of 3.14% [22] - Zhejiang Communications Technology's subsidiary won two projects totaling over 3.4 billion yuan [23] - Feilong Co. received a notification from SAIC Motor for a designated sales agreement, expecting sales revenue of over 400 million yuan during its lifecycle [24] - Liuyuan Group plans to repurchase shares worth 100 million to 200 million yuan [25] - Meikailong's shareholders plan to reduce their holdings by no more than 3.0011% of the company's shares [26]

Group 1 - Liu Pharmaceutical Group plans to repurchase shares worth between 100 million and 200 million yuan, with a maximum repurchase price of 25.70 yuan per share [1] - Dongshan Precision intends to invest up to 1 billion USD to build a high-end printed circuit board project to meet the long-term demand for high-end printed circuit boards in emerging scenarios such as AI [1] - Bomaike reported a net profit of 12.39 million yuan for the first half of the year, a year-on-year decline of 80.42% [2] Group 2 - Western Mining achieved a net profit of 1.869 billion yuan in the first half of the year, a year-on-year increase of 15% [2] - Fuliwang expects a net loss of approximately 17 million yuan for the first half of the year, a decrease of 137.12% compared to the same period last year [2] - Digital Certification anticipates a net loss of between 80 million and 96 million yuan for the first half of the year, compared to a loss of 29.25 million yuan in the same period last year [3] Group 3 - Shanghai Construction reported a net profit of 710 million yuan for the first half of the year, a year-on-year decrease of 14.04% [5] - Funneng Co. achieved a net profit of 1.337 billion yuan in the first half of the year, a year-on-year increase of 12.48% [6] - Tengda Construction's total contract amount for the first half of the year decreased by 17.55% year-on-year [7] Group 4 - Fudan Fuhua decided to terminate the public transfer of a 28% stake in a subsidiary due to the lack of a deposit from potential buyers [9] - Fulei Ant's subsidiary has decided to cease operations due to intense competition in the photovoltaic industry and ongoing losses [11] - Dongfang Ocean's subsidiary received a medical device registration certificate for a folic acid testing kit [14] Group 5 - Huayu Pharmaceutical's subsidiary received overseas listing approvals for several products [16] - Feima International received a performance commitment compensation of 437 million yuan from its controlling shareholder [16] - Guangshen Railway signed a cooperation agreement for the Guangzhou East Station renovation project with a total investment of approximately 16.66 billion yuan [16] Group 6 - Anhui Construction won the bid for the S68 Jingde to Jixi Expressway project with an estimated total investment of 5.7 billion yuan [18] - China Communications Construction Company signed new contracts worth 991.054 billion yuan in the first half of the year, a year-on-year increase of 3.14% [19] - Kehui Co. plans to use up to 70 million yuan of idle funds for cash management [22] Group 7 - Biological Shares' subsidiary received a clinical trial approval for a cat mRNA vaccine, the first of its kind in China [23] - Ruipu Biological received a clinical trial approval for a pig mRNA vaccine, which is the first economic animal mRNA vaccine in China [24] - Nanjing New Hundred's major assets were judicially frozen due to liquidity debt crisis faced by its controlling shareholder [27] Group 8 - Changshu Bank plans to merge three village banks and establish branches, pending shareholder approval [28] - Yong'an Pharmaceutical plans to reduce its holdings by up to 2.6323 million shares [29] - Zhujiang Co. received approval from the Shanghai Stock Exchange for a stock issuance to specific targets [31] Group 9 - Sanyangma's subsidiary signed a 120 million yuan procurement contract for sensor products [33] - Jintou City Development plans to purchase a villa property for approximately 7.1854 million yuan [35] - Yuanli Co. intends to acquire 100% of Tongsheng Co. through a combination of cash and stock issuance [36] Group 10 - Xin'an Century's controlling shareholder plans to reduce holdings by up to 2.22% of the company's shares [36] - Fute Technology plans to raise up to 528 million yuan through a private placement for various projects [36] - Helen Piano's actual controller is set to change, with stock resuming trading [37] Group 11 - Weiergao expects a net profit increase of 12.55% to 30.87% for the first half of the year [38] - Saiwei Microelectronics plans to transfer up to 18% of its shares through an agreement [40] - Yongli Co. intends to acquire a 22.75% stake in a subsidiary [42] Group 12 - ST Xiachuang plans to publicly transfer a 20% stake in Guangdong Yuweiji [43] - Dema Technology's shareholders plan to transfer 778.84 million shares through an inquiry [45] - Zhongshi Technology's shareholders plan to reduce holdings by up to 2.86% of the company's shares [46] Group 13 - Wufang Optoelectronics' controlling shareholder plans to reduce holdings by up to 0.93% of the company's shares [48] - Fusenmei's chairman has been detained, temporarily unable to fulfill his duties [49] - Reliable Co.'s shareholders plan to reduce holdings by a total of up to 2.63% of the company's shares [51] Group 14 - Gao Neng Environment plans to repurchase shares worth between 100 million and 150 million yuan [53]

Corporate Announcements - Sanfeng Intelligent's director Chen Wei has been placed under investigation, but the company's operations remain normal and unaffected [3] - Shanghai Pharmaceuticals plans to acquire a 10% stake in Shanghai Shihua Group Financial Company for 143 million yuan, increasing its ownership from 30% to 40% [4] - Western Gold intends to acquire 100% of Xinjiang Meisheng Mining for 1.655 billion yuan, with a premium of 1421.66% over book value; the target company is expected to commence production in the second half of 2025 [5] - Hengrui Medicine plans to acquire approximately 1.46% of Chengdu Shengdi Pharmaceutical from minority shareholders for 40.144 million yuan, increasing its stake to 97.37% [6] - Dongshan Precision has approved an investment of up to 1 billion USD for a high-end printed circuit board project to meet long-term demand in emerging markets [7] - ST Wanfang and Rebecca have both received notices from the China Securities Regulatory Commission regarding investigations into information disclosure violations, but their operations remain normal [8][9] Financial Performance - China Duty Free Group reported a net profit of 2.6 billion yuan for the first half of 2025, a decrease of 20.81% year-on-year, with total revenue of 28.151 billion yuan, down 9.96% [13] - Digital Certification expects a loss of 80 to 96 million yuan for the first half of 2025, compared to a loss of 29.25 million yuan in the same period last year [14] - Western Mining reported a net profit of 1.869 billion yuan for the first half of 2025, an increase of 15% year-on-year, with total revenue of 31.619 billion yuan, up 27% [15] Major Contracts - ST Dongyi signed new orders worth 215 million yuan in the second quarter for its decoration business, with total uncompleted contracts amounting to 383 million yuan [17] - Guangshen Railway signed a cooperation agreement for the Guangzhou East Station renovation project, with a total investment of approximately 16.66 billion yuan [18] Shareholder Actions - Huajin Technology's employee stock ownership platform plans to reduce its stake by up to 4% within three months [20] - Liuyuan Group intends to repurchase shares worth between 100 million and 200 million yuan, with a maximum repurchase price of 25.7 yuan per share [22]

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-053 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于以集中竞价交易方式回购股份方案的公告 ● 回购股份价格：不超过人民币 25.70 元/股（含），该价格不高于董事会审 议通过回购方案决议前 30 个交易日公司股票交易均价的 150%。 ● 回购股份方式：集中竞价交易方式。 ● 回购股份期限：自董事会审议通过本次回购方案之日起不超过 12 个月。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 广西柳药集团股份有限公司（以下简称"公司"）基于对未来发展前景的信心 和对公司长期价值的高度认可，为推动公司股票价值的合理回归，稳定投资者预 期，增强市场信心，维护公司和全体股东的利益，并进一步落实"提质增效重回 报"行动方案，公司拟以集中竞价交易方式回购公司发行的部分人民币普通股 A 股股份。主要内容如下： ● 回购股份金额：不低于人民币 10,000 ...

柳药集团（603368）公告，公司拟以集中竞价交易方式回购公司发行的部分人民币普通股A股股份。回 购金额不低于人民币1亿元(含)，不超过人民币2亿元(含)，资金来源为公司自有资金和自筹资金。回购 股份价格不超过人民币25.7元/股(含)，预计回购股份数量约为389.11万股~778.21万股，占公司总股本的 0.98%~1.96%。回购股份用途为拟在未来适宜时机用于实施股权激励及/或员工持股计划；若公司未能在 本次股份回购完成后3年内实施上述用途，则未使用的已回购股份将履行相关程序予以注销。 ...

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-052 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 回购注销原因：广西柳药集团股份有限公司（以下简称"公司"）2023 年限制性股票激励计划（以下简称"本激励计划"）中的 1 名预留授予激励对象 因个人原因离职而不再具备激励资格，公司决定对其持有的已获授但尚未解除限 售的 3,000 股限制性股票予以回购注销；因公司决定终止实施本激励计划，公司 需回购注销除上述1名离职激励对象以外的181名激励对象已获授但尚未解除限 售的 1,692,050 股限制性股票。 ● 本次注销股份的有关情况： | 回购股份数量 | 注销股份数量 | | 注销日期 | | | | | --- | --- | --- | --- | --- | --- | --- | | 股 1,695, ...

关于 广西柳药集团股份有限公司 2023 年限制性股票激励计划 限制性股票回购注销实施的 法律意见书 法律意见书 深圳市福田区深南大道 4011 号香港中旅大厦 21-26 层 邮政编码（Postcode）：518048 21-26/F, HKCTS Tower, 4011 Shennan Road, Futian District, Shenzhen, P. R. China 电话（Tel.）：0086-755-83025555 传真（Fax.）：0086-755-83025068 网址（Website）：www.huashanglawyer.com | 释 | 义 iii | | --- | --- | | 第一节 | 法律意见书引言 i | | 第二节 | 法律意见书正文 1 | | | 一、本次回购注销的批准和授权 1 | | | 二、本次回购注销的原因、数量、回购价格和资金来源等情况 7 | | | 三、本次回购注销的实施进展 10 | | | 四、结论性意见 11 | 在《广东华商律师事务所关于广西柳药集团股份有限公司 2023 年限制性股 票激励计划限制性股票回购注销实施的法律意见书》中，除上下 ...

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-051 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于公司及下属控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 广西柳药集团股份有限公司（简称"公司"） 万元 | | --- | --- | --- | --- | | | 本次担保金额 | 500.00 | | | 担保 对象一 | 实际为其提供的担保余额 | 15,530.83 | 万元（含本次） | | | 是否在前期预计额度内 | 是 | □否 不适用：_________ | | | 本次担保是否有反担保 | □是 | 否 不适用：_________ | | 担保 | 被担保人名称 | | 广西南宁柳药药业有限公司（简称"南宁柳药"） | | | 本次担保金额 | 13,714.17 | 万元 | | 对象二 ...

● 累计转股情况：截至 2025 年 6 月 30 日，累计人民币 321,000 元"柳药 转债"已转换成公司股份，占可转债发行总量的 0.0400%；累计转股数量为 13,180 股，占可转债转股前公司发行股份总额的 0.0036%。 证券代码：603368 证券简称：柳药集团 公告编号：2025-050 转债代码：113563 转债简称：柳药转债 广西柳药集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： "柳 ● 未转股可转债情况：截至 2025 年 6 月 30 日，尚未转股的"柳药转债" 金额为人民币 801,879,000 元，占可转债发行总量的 99.9600%。 一、可转债发行上市概况 经中国证券监督管理委员会《关于核准广西柳州医药股份有限公司公开发行 可转换公司债券的批复》（证监许可20192303 号）核准，广西柳药集团股份有 限公司（以下简称"公司"）于 2020 年 1 月 16 日公开发行 802.20 万张可转换 公司债券，每张面值 ...